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Abstract
The physiological actions of somatostatin-14 (SRIF: somatotrophin release inhibitory factor) receptor subtypes (sst1–sst5), which
are endogenously expressed in growth cells (GC cells), have not yet been elucidated, although there is evidence that sst2 receptors
are negatively coupled to cytosolic free Ca2+ concentration ([Ca2+]i) and adenosine 3,5’-cyclic monophosphate (cAMP) accumulation.
In addition, both sst1 and sst2 receptors are negatively coupled to growth hormone (GH) secretion in GC cells. Here we report on
studies concerning the expression, the pharmacology and the functional role of native SRIF receptors in GC cells with the use of
five nonpeptidyl agonists, highly selective for each of the SRIF receptors. Radioligand binding studies show that sst2 and sst5
receptors are present at different relative densities, while the presence of sst3 and sst4 receptors appears to be negligible. The absence
of sst1 receptor binding was unexpected in view of sst1 receptor functional effects on GH secretion. This suggests very efficient
receptor–effector coupling of a low-density population of sst1 receptors. Functionally, only sst2 receptors are coupled to the inhibition
of [Ca2+]i and cAMP accumulation and the selective activation of sst5 receptors facilitates the stimulation of adenylyl cyclase activity
through Gi/o proteins. This effect was not observed when sst2 and sst5 receptors were simultaneously activated, suggesting that there
is a functional interaction between sst2 and sst5 receptors. In addition, sst1, sst2 and sst5 receptor activation inhibits GH release,
further indicating that SRIF can modulate GH secretion in GC cells through mechanisms both dependent and independent on [Ca2+]i
and cAMP-dependent pathways. The present data suggest SRIF-mediated functional effects in GC cells to be very diverse and
provides compelling arguments to propose that multiple native SRIF receptors expressed in the same cells are not simply redundant,
but contribute to marked signalling diversity.
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1. Introduction
Somatostatin-14 (SRIF: somatotrophin release inhibi-
tory factor) originally discovered as a hypothalamic
inhibitor of growth hormone (GH) secretion, acts
through at least five distinct heptahelical, G-protein-
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coupled SRIF receptor subtypes (sst1–sst5; Benali et al.,
2000). The action of SRIF receptor activation on both
cytosolic free Ca2+ concentration ([Ca2+]i) and adenosine
3,5-cyclic monophosphate (cAMP) levels is critically
relevant to SRIF’s physiological role as an inhibitor of
secretion (Patel, 1999). In particular, in rat somatotrophs,
SRIF-induced inhibition of GH secretion is due, at least
in part, to the inhibition of [Ca2+]i and cAMP levels
(Djordjijevic et al., 1998; Epelbaum et al., 1994; Lussier
et al., 1991; Tomic et al., 1999b). The precise involve-
ment of SRIF receptors in these effects is, however,
